In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Retatrutide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 380 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 61 (61 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 34 · 11 active | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Retatrutide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 32266 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 987919 | 83481717 |
|---|
| Adverse eventsWhole body | 3838 | 50449311 |
|---|
| Heart functionCardiovascular | 8215 | 214198142 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1717 | 185185 |
|---|
| LipidsMetabolic and weight | 271611 | 14313733 |
|---|
| Liver fat and liver functionLiver | 20137 | 1361279 |
|---|
| Blood pressureCardiovascular | 44 | 1201182 |
|---|
| Appetite and food intakeMetabolic and weight | 19136 | 1129517 |
|---|
| Inflammation markersLiver | 14410 | 117100152 |
|---|
| Kidney functionKidney and urinary | 1495 | 1049932 |
|---|
| PharmacokineticsPharmacology | 66 | 969231 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Retatrutide differs from Gastric inhibitory polypeptide (GIP) at 15 positions and in 1 end segment.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Retatrutide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | −1.69% HbA1c change · retatrutide 4 mg Dose studied: 4 mg once weekly40 weeksn not reported2026 | −1.48% HbA1c change · liraglutide 1.8 mg Dose studied: 1.8 mg once daily26 weeksn = 7762013 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −13.8% Treatment difference vs placebo · retatrutide 12 mg Dose studied: 12 mg80 weeksn = 5762026 | |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | −37% UACR difference vs placebo · retatrutide 12 mg, T2D, week 36 Dose studied: 12 mg36 weeksn not reported2025 | −40.2% UACR change |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 14% Participants with nausea · retatrutide 4 mg Placebo: 8% Dose studied: 4 mgn = 5792026 | 45% |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 63% Treatment-emergent adverse events · LY3437943 Placebo: 54% Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 722022 |
−1.69%
HbA1c change · retatrutide 4 mg
Dose studied: 4 mg once weekly40 weeksn not reported2026
−1.48%
HbA1c change · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 7762013
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Retatrutide | Liraglutide |
|---|---|---|
| SleepSleepCompared as: difference from placebo, in events h(-1) | No comparable result 6 randomized-trial results measure it in another way or another unit. | −6.1 events h(-1) Estimated treatment difference Dose studied: 3.0 mg32 weeksn = 3592016 |
−5.8% Placebo-subtracted body weight change · liraglutide 3.0 mg, week 26 Dose studied: 3.0 mg26 weeksn not reported2021 |
Dose studied: 1.2-1.8 mg/d26 weeks (after 6 weeks of titration)n = 392019
Nausea incidence
8 weeksn = 202015
89% Adverse events Placebo: 88% Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025 |
−13.8%
Treatment difference vs placebo · retatrutide 12 mg
Dose studied: 12 mg80 weeksn = 5762026
−5.8%
Placebo-subtracted body weight change · liraglutide 3.0 mg, week 26
Dose studied: 3.0 mg26 weeksn not reported2021
−37%
UACR difference vs placebo · retatrutide 12 mg, T2D, week 36
Dose studied: 12 mg36 weeksn not reported2025
−40.2%
UACR change
Dose studied: 1.2-1.8 mg/d26 weeks (after 6 weeks of titration)n = 392019
14%
Participants with nausea · retatrutide 4 mg
Placebo: 8%
Dose studied: 4 mgn = 5792026
45%
Nausea incidence
8 weeksn = 202015
63%
Treatment-emergent adverse events · LY3437943
Placebo: 54%
Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 722022
89%
Adverse events
Placebo: 88%
Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No comparable result 4 randomized-trial results measure it in another way or another unit. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No comparable result 11 randomized-trial results measure it in another way or another unit. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Heart functionCardiovascularCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 4.7% Difference in LVEF change Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016 |
|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in % | No comparable result 12 randomized-trial results measure it in another way or another unit. | −44% Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size. Dose studied: 1.8 mg/d26 weeksn = 722018 |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No comparable result 10 randomized-trial results measure it in another way or another unit. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 2 randomized-trial results measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
No comparable result
6 randomized-trial results measure it in another way or another unit.
−6.1 events h(-1)
Estimated treatment difference
Dose studied: 3.0 mg32 weeksn = 3592016
No comparable result
4 randomized-trial results measure it in another way or another unit.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No comparable result
11 randomized-trial results measure it in another way or another unit.
21 lipids
Lipids decreased
26 weeksn = 1022021
No comparable result
1 randomized-trial result measure it in another way or another unit.
4.7%
Difference in LVEF change
Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016
No comparable result
12 randomized-trial results measure it in another way or another unit.
−44%
Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size.
Dose studied: 1.8 mg/d26 weeksn = 722018
No comparable result
10 randomized-trial results measure it in another way or another unit.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No comparable result
2 randomized-trial results measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 34 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company10,000 participants30 Apr 2024 to est. Feb 2029
Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Eli Lilly and Company4,500 participants15 Oct 2025 to est. Aug 2032
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company2,335 participants10 Jul 2023 to 30 Apr 2026
Obesity · Overweight · Osteoarthritis, Knee · Obstructive Sleep Apnea
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.